Article Details
Retrieved on: 2025-01-24 20:09:13
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
First Patient Dosed in Phase 3 Trial for Intellia Therapeutics' Hereditary Angioedema Gene Editing Therapy NTLA-2002. The company stated it expects ...
Article found on: www.cgtlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here